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Introduction
Multidrug resistance (MDR) acquired during previous cycles 
of chemotherapy seems to be of relevance for the chemotherapy 
of head and neck squamous cell carcinoma (HNSCC), because 
studies enrolling such patients for second line treatment demon-
strated considerably lower response rates than studies excluding 
pre-treated patients.1 The classical MDR phenotype is mediated 
by ATP-binding cassette (ABC)-transporters extruding antican-
cer agents or their metabolites from cells thus mediating drug 
resistance.2 Paclitaxel, cisplatin, and 5-fluorouracil (5-FU) are 
standard anti-HNSCC drugs3 whose efficacies are limited by 
several ABC-transporters at least in vitro.4-9 In addition, efficacy 
of cisplatin is also influenced by transporters involved in copper 
homeostasis. Human copper transporter 1 (hCTR1/SLC31A1) 
mediates the cellular uptake of copper, cisplatin, and oxalipla-
tin.10 The P-type ATPase ATP7b is also associated with trans-
port and resistance to platinum-containing drugs.11 In HNSCC, 
these drug transporters are expressed and their expression levels 
are increased in vitro upon exposure to paclitaxel, cisplatin, or 
5-FU.12 However, there is very little clinical data reporting post-
chemotherapeutic expression levels of MDR proteins. Moreover, 
the potential mechanistic tropism of this condition is unclear. 
However, it is well known that the expression of ABC-transporters 
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Drug-induced multidrug resistance (MDR) has been linked to overexpression of drug transporting proteins in head 
and neck squamous cell carcinoma (hNsCC) in vitro. The aim of this work was to reassess these findings in a murine 
xenograft model.
NOD-sCID mice xenotransplanted with 106 hNO97 cells were treated for four consecutive weeks with weekly 
paclitaxel, biweekly cisplatin (both intraperitoneal), or 5-fluorouracil (5-FU, administered by osmotic pump). Tumor 
volume and body weight were weekly documented. expression of drug transporters and Ki-67 marker were examined 
using quantitative real-time polymerase chain reaction and/or immunohistochemistry.
Both paclitaxel and cisplatin significantly reduced tumor volumes after 2–3 weeks. 5-FU-treated animals had 
significantly lower body weights after 2 or 4 weeks of chemotherapy. None of the drugs affected expression of drug 
transporters at the mRNA level. however, P-glycoprotein (Pgp) protein expression was increased by paclitaxel (P < 0.01). 
Ki-67 expression did not change during treatment irrespective of the drug applied.
Paclitaxel and cisplatin are effectively tumor volume reducing drugs in a murine xenograft model of hNsCC. Paclitaxel 
enhanced Pgp expression at the protein level, but not at the mRNA level suggesting transcriptional induction to be 
of minor relevance. In contrast, posttranscriptional mechanisms or Darwinian selection of intrinsically drug transporter 
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is regulated by xenobiotic sensing nuclear factors such as preg-
nane-x-receptor (PXR, NR1I2)13 affecting the transcription of 
such target genes thus mediating drug–drug interactions and 
chemotherapy resistance.14-18
To fill the gap between in vitro studies and ex vivo tumor 
evaluations and in order to reassess in vitro findings, we evalu-
ated anti-HNSCC efficacies and drug transporter and PXR 
inducing properties of paclitaxel, cisplatin, or 5-FU in a murine 
xenotransplantation model through recording of tumor volume 
and measuring respective expression levels by quantitative real-
time polymerase chain reaction and immunohistochemistry.
Results
Evaluation of antiproliferative efficacies
Tumor volumes of mock-treated animals nearly doubled dur-
ing study phase. 5-FU-treated mice also demonstrated increases 
of tumor volumes with no statistically significant differences to 
mock-treated animals at any time point evaluated (Fig. 1A).
In the paclitaxel/cisplatin/control arm, the mock-treated ani-
mals again exhibited clear increases of tumor volume. In contrast, 
tumor growth and tumor volumes were significantly reduced by 
paclitaxel throughout the observation period and cisplatin after 
two and three weeks of chemotherapy, respectively (Fig. 1B).
Effect of cytostatics on mRNA and protein expression levels
Expression levels of the transporters investigated was assessed 
at the mRNA level by quantitative real-time RT-PCR and at the 
protein level by immunohistochemistry.
PXR and ATP7b (5-FU arm) were too low expressed to be 
properly quantified by qRT-PCR. 5-FU had no effect on mRNA 
expression levels. ABCG2 tended to be suppressed by cispla-
tin and ABCC2 tended to be downregulated by both cisplatin 
and paclitaxel. However, none of the drugs significantly altered 
mRNA expression levels (Fig. 2A and B).
Protein expression levels were evaluated by a multiplication 
score reflecting both staining intensity and extent of stained cells. 
Consequently, increases in expression values (Fig. 3) result from 
either enhanced intensity, enhanced number of expressing cells, 
or both. hCTR1 tended to be downregulated by 5-FU (Fig. 3A), 
cisplatin, and paclitaxel (Fig. 3B), but without statistical signifi-
cance. Cisplatin and paclitaxel also non-significantly increased 
expression of MRP2 (Fig. 3B). In contrast, paclitaxel did sig-
nificantly enhance protein expression of Pgp (P < 0.01) (Figs. 3B 
and 4).
Effects of cytostatics on body weight
5-FU treatment delayed the natural weight gain of the ten 
weeks old mice. Differences in body weight were statistically sig-
nificant after two (P = 0.0052) and four (P = 0.0355) weeks of 
chemotherapy with 5-FU.
Paclitaxel had no effect on body weight, whereas cisplatin 
tended to reduce it throughout the observation period. However, 
the effects did not reach statistical significance (P > 0.05).
Effects of cytostatics on Ki-67 staining
Drug treatments did not change the percentage of Ki-67 posi-
tively stained nuclei. Mean values (5-FU, 12.6%; control, 5.2%; 
paclitaxel, 14.0%; cisplatin, 5.8%; control, 12.5) did not differ 
significantly.
Discussion
Acquired chemotherapy resistance is an unsolved problem in 
the treatment of HNSCC. For instance, patients with previous 
chemotherapy demonstrated lower response rates to second line 
treatment than patients who were not pre-treated.1 The relevance 
of drug transporters for such clinical chemotherapy resistance in 
HNSCC is largely unknown. Some data from in vitro studies 
demonstrate exposure to typical anti-HNSCC drugs to influence 
both drug transporter expression and subsequent drug sensitivity 
of HNSCC cell lines. In detail, especially paclitaxel exhibited high 
potency to induce drug transporters and to cause high resistance 
to paclitaxel or cisplatin (cross-resistance).12 This recent data was 
in line with findings in other cancer entities or cell models.4,19-21 
Now, the results of this in vivo approach partly confirm these 
earlier findings on paclitaxel’s potency to induce expression of 
Figure 1. Antiproliferative effects of cytostatics. Tumor volumes were normalized to each individual mouse and are reported relatively to initial tumor 
volume set to 1. (A) 5-FU vs control. Data are expressed as mean ± seM for n = 9–10. statistical significance was evaluated using non-parametric Mann–
Whitney test comparing tumor volumes at respective time points. (B) Paclitaxel or cisplatin vs control. Data are expressed as mean ± seM for n = 6–13. 
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drug transporters, especially that of Pgp.19,20 In contrast to 5-FU 
or cisplatin, paclitaxel was the only cytostatic leading to a signifi-
cant induction of Pgp expression. However, this enhancement 
was only detectable at the protein level (Figs. 3B and 4) and not 
at the mRNA level (Fig. 2B). In theory, increased expression of 
MDR transporters after cytotoxic drug exposure can be caused by 
two mechanisms. First, Darwinian selection eradicating sensitive 
cells and concurrently promoting ABC-transporter overexpress-
ing drug resistant cells, that are clonally selected when exposed 
to cytostatic drugs.22-24 Genetic instability favors this mecha-
nism,25,26 that has also been described in HNSCC.27,28 Together, 
Darwinian selection is a probable scenario also in our HNSCC 
study since paclitaxel exposure sustainably reduced tumor vol-
ume (Fig. 1B) indicating cytoreduction of sensitive cells, while 
Pgp overexpressing cells withstood the drug exposure. Second, 
transcriptional mechanisms leading to enhanced expression of 
transporter genes. For such transcriptional induction, nuclear 
receptors (e.g., PXR) need to be expressed and functionally 
active.13 Under these prerequisites, paclitaxel is known to bind to 
PXR, to activate it, and to finally lead to enhanced transcription 
of its main target genes such as ABCB1 (Pgp). When PXR is how-
ever absent (e.g., via RNA interference mediated knock-down), 
induction is shut down or at least diminished.29,30 In consequence, 
the clear-cut missing alterations of ABCB1 mRNA expression 
levels in our mouse model might be related to functionality of 
PXR, because the PXR protein itself is obviously expressed (Fig. 
3A and B). Indeed, during the course of this study we simulta-
neously characterized PXR functionality in vitro in a subset of 
HNSCC cell lines through PXR reporter-gene assays. Surpris-
ingly, 6 out of 8 cell lines exhibited non-functional PXR. The cell 
line HNO97 was also demonstrated to express malfunctioned 
PXR, because even strong inducers such as rifampicin failed to 
Figure 2. effect of cytostatics on mRNA expression levels of drug transporters. (A) Tumor mRNA expressions of 5-FU treated animals were normalized to 
mock-treated controls. NR1I2 and ATP7b were too low expressed to be properly quantified. Data are expressed as mean ± seM for n = 4–10. statistical sig-
nificance was evaluated by non-parametric Mann–Whitney test. (B) Tumor mRNA expressions of paclitaxel- or cisplatin-treated animals were normalized 
to mock-treated controls. NR1I2 was too low expressed to be properly quantified. Data are expressed as mean ± seM for n = 5–8. statistical significance 
was evaluated by non-parametric ANOVA with Kruskal–Wallis post-hoc test.
Figure 3. effect of cytostatics on protein expression levels of drug transporters and PXR. (A) Tumor protein expression levels of 5-FU treated animals 
compared with mock-treated controls. Data are expressed as mean ± seM for n = 6–10. statistical significance was evaluated by non-parametric Mann–
Whitney test. (B) Tumor expression levels of paclitaxel- or cisplatin-treated animals compared with mock-treated controls. Data are expressed as mean ± 
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activate it.31 Consequently, it is quite comprehensible why 
in this current study with HNO97 cells, drug transporters 
were universally not induced at the transcriptional mRNA 
level, because PXR is obviously dysfunctional in this cell 
line. Thus, alternative mechanisms such as posttranscrip-
tional regulation or selection processes might have led to the 
punctual overexpression of Pgp, the most prominent and 
most important MDR mediating ABC-transporter.2
Despite our disease-oriented mouse model is expected 
to reflect clinical manifestation of HNSCC more precisely 
than in vitro approaches,32 this study also has some limita-
tions. Ki-67 expressions did not change upon drug expo-
sure indicating absent inhibition of tumor cell proliferation. 
However, induction of apoptosis could alternatively have 
led to the observed significant reductions of tumor volumes 
by paclitaxel and cisplatin. Moreover, xenograft models are 
partly disadvantageous for representation of human cancer 
disease, because cell lines differ from natural tumor and 
have adapted to cell culture conditions over years or even 
decades. Alternatively, genetically modified mouse models 
(knockout of p53 and/or BRCA1) spontaneously develop-
ing tumors are state-of-the-art approaches to study drug 
resistance.33 However, some of these obvious downsides do 
not apply to our approach. First, we intended to investigate 
induction of human drug transporters. Murine transporters 
are unequally to their human counterparts and are regulated 
in a different manner. Consequently, xenotransplantation of 
human cells is mandatory for our purpose. Second, the HNSCC 
cell line used (HNO97) has been demonstrated to reliably repre-
sent HNSCC with documented original tumor characteristics.34 
Taken together, we are convinced that this approach is suitable 
for the investigation of drug effects on expression of human drug 
transporters in HNSCC, despite assignability to HNSCC in gen-
eral is probably invalid, because only one cell line has been inves-
tigated. Moreover, other results (potent inductions at mRNA and 
protein level) could also have been achieved with one of the few 
exceptional cell lines exhibiting proper PXR function.31
In conclusion, this study used a murine xenotransplantation 
model for HNSCC and demonstrates that paclitaxel and cispla-
tin are effectively tumor volume reducing cytostatics. Paclitaxel 
additionally enhanced Pgp protein expression. At the mRNA 
level, however, none of the drugs had inductive effects suggest-
ing transcriptional mechanisms to be of minor relevance. In con-
trast, posttranscriptional mechanisms and Darwinian selection 
of intrinsically transporter overexpressing MDR cells might be 




Culture media, medium supplements, PBS, antibiotics, and 
5-FU, were purchased from Sigma-Aldrich. Fetal calf serum 
(FCS) was purchased from PAA. Cisplatin and paclitaxel were 
from the university hospital’s pharmacy. The antibodies against 
PXR (G-11) and hCTR1 (G15) and the ImmunoHistoMount 
mounting medium were obtained from Santa Cruz Biotech-
nology. The antibody against breast cancer resistance protein 
(BCRP) was from Alexis Biochemicals. Anti-P-glycoprotein 
(Pgp) antibody (C219) was from Calbiochem. Anti-multidrug 
resistance associated protein 2 (MRP2) antibody (M2III-6) 
was from Thermo. Anti-ATP7b antibody was from Acris. Anti-
MRP5 antibody was from GeneTex. Anti-Ki-76 antibody and 
BD Matrigel were from Beckton Dickinson. The Vectastain Elite 
ABC Kits including the anti-mouse, anti-goat, anti-rat, or anti-
rabbit IgG peroxidase linked secondary antibodies and the AEC 
Substrate Kit were from Vector Laboratories. Mayer’s Haemalaun 
solution was purchased from Merck. The RNeasy Kit was from 
Qiagen and the RevertAid™ H Minus First Strand cDNA Syn-
thesis Kit was from Fermentas, and the qPCR SYBR Green Mix 
was purchased from Abgene. Osmotic pumps (model 1004) and 
respective filling tubes were from Charles River.
Murine xenograft model for HNSCC
The HNSCC cell line used (HNO97) was authenticated 
and has been derived from an intraoperatively obtained sample, 
established, and characterized as reported previously.35 Suitabil-
ity of this cell line for representation of HNSCC was recently 
confirmed by comprehensive tumor cell biological character-
ization.34 HNO97 cells were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% heat inactivated FCS, 
100 U/ml penicillin, and 100 μg/ml streptomycin sulfate.
Six-week-old, female, NOD-SCID mice were purchased from 
Charles River and were handled under governmental and insti-
tutional rules and regulations after approval by the respective 
authorities. Animals were housed under specific pathogen-free 
Figure  4. Representative images of tissue slices stained for Pgp expression. 
(A) Negative control (tumor slice treated with secondary antibody only); (B) 
Positive control (liver) showing typical Pgp expression at the canalicular mem-
brane of hepatocytes; (C) Tumor Pgp expression in a mock-treated animal; (D) 
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conditions with a 12 h light/dark cycle and received food and tap 
water ad libitum.
Briefly, 1 × 106 cells (suspended in 200 μl BD Matrigel) 
were subcutaneously injected at the right flank of the mice 
under general anesthesia using ketamine (75 mg/kg) and xyla-
zine (25 mg/kg). Three weeks after xenotransplantation, when 
tumors had reached a volume of approximately 300 mm3, mice 
were randomized into treatment groups (Fig. 5).
Chemotherapeutic treatments
Paclitaxel and cisplatin dosing was based on previous studies 
on HNSCC xenograft models. Paclitaxel (10 μg/g) was injected 
intraperitoneally once weekly,36 whereas cisplatin (1 μg/g) was 
administered twice a week.37 Because of its short elimination half-
time and to mimic clinical infusion administration, 5-FU was 
administered using an osmotic pump (0.11 μl/h flow) implanted 
into the peritoneal cave (Fig. 5).38 This pump delivered 1.75 mg 
of 5-FU in total over four weeks of treatment.
Placebo treatments consisted of either vehicle injections (con-
trol for paclitaxel or cisplatin, respectively) or vehicle-delivering 
pumps (control for 5-FU).
Evaluation of antiproliferative efficacies
Cytostatic efficacies were evaluated weekly by measurement 
of tumor volume calculated by the following equation: tumor 
volume = (a × b2)/2, where a represents the length of the tumor 
and b the width.
Ki-67 staining index was evaluated through immunohisto-
chemistry. Histological sections were automatically imaged in a 
40× magnification (resolution: 0.23 μm/pixel) using the Hama-
matsu NanoZoomer 2.0-HT Scan System (Hamamatsu Photon-
ics). For the scanning of the object slides, the slide scanner auto-
matically detects the region of interest (ROI) that contains the 
tissue and also determines automatically a valid focal plane for 
scanning. The image processing algorithms have been developed 
using TissuemorphDP™ version 4.5.1 (Visiopharm). Software 
was developed on a Personal Computer: 64 Bit, Intel Quad-
Core i7 @ 3.40 GHz and 8GB RAM with Microsoft Windows 
7 operating system. The first image processing step involves a 
segmentation of all nuclei in previously manual selected ROIs. 
ROIs were selected by including all tissue areas of the whole slide 
by omitting fragmented and folded areas. The segmentation was 
done by a watershed segmentation39,40 on the IHS-S color band. 
Then the positive nuclei were detected within a HDAB-DAB 
color band, provided by a color deconvolution algorithm.41 As a 
post-processing step, areas that were too small where removed by 
an area-filter. Percent of positively strained nuclei were consid-
ered the relevant output variable.
Quantification of mRNA expressions by quantitative real-
time reverse transcription polymerase chain reaction (qRT-
PCR)
After four weeks of chemotherapy, mice were sacrificed 
through spinal cord dislocation and tumors were immediately 
removed and frozen in ice-cold isopentane and stored at −80 °C 
until further analysis. RNA was isolated from tumor specimen 
using RNeasy-Kit and cDNA was synthesized with the Rever-
tAid™ H Minus First Strand cDNA Synthesis Kit according to 
the manufacturer’s instructions. Expression of mRNA was quan-
tified by qRT-PCR with a LightCycler® 480 (Roche Applied Sci-
ence) using the SYBR Green format with the Absolute QPCR 
SYBR Green Mix. Primer sequences were published previ-
ously.12 The following genes were quantified: NR1I2 (encod-
ing for PXR), ABCB1 (encoding for Pgp), ABCC2 (encoding 
for MRP2), ABCC5 (encoding for MRP5), ABCG2 (encoding 
BCRP), SLC31A1 (encoding hCTR1), and ATP7b (also called 
Wilson disease protein). The most suitable housekeeping gene 
for normalization was identified using geNorm (version 3.4, 
Center for Medical Genetics).42 Among the housekeeping genes 
tested (β2-microglobulin; glucose-6-phosphate dehydrogenase, 
G6PDH; glucuronidase β; ribosomal protein L13 (RPL13); 
hypoxanthine-phosphoribosyltransferase 1, HPRT; 60S (human) 
acidic ribosomal protein P1 (HUPO), G6PDH/HUPO proved to 
be the most stable ones for the 5-FU/control arm and G6PDH/
HPRT for the paclitaxel/cisplatin/control data set. Data were 
Figure 5. experimental schedule: Three weeks after subcutaneous (s.c.) xenotransplatation of 106 hNO97 cells, chemotherapy was initiated, that lasted 
for four consecutive weeks. One representative week is shown in detail: Paclitaxel (black arrows) or cisplatin (gray arrows) were administered once or 
twice a week, respectively. Tumor volume (caliper symbol) and body weight (scale symbol) were evaluated once a week. 5-FU administration was medi-
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evaluated by calibrator-normalized relative quantification with 
efficiency correction using LightCycler® 480 software as pub-
lished previously.43 Results are expressed as the ratio of target 
gene/housekeeping genes divided by the corresponding ratio of 
the calibrator (cDNA of the HNO97 cell line). All samples were 
amplified in duplicate.
Quantification of protein expressions by immunohisto-
chemistry
Stored tumor specimens were cut into 5 μm slices with a 
cryostat (Leica CM 1850 UV from Leica Biosystems) and were 
evaluated for drug transporter expression by immunohistochem-
istry according to manufacturer’s instructions. All steps were 
performed in a humidity chamber at room temperature. In brief, 
after thawing and drying of object slides, tumor specimens were 
exposed for 1 h to 40 μl of diluted antigen-specific antibodies. 
After washing 3 × 5 min with PBS, 40 μl of diluted secondary-
antibodies were applied for 30 min. After washing 3 × 5 min with 
PBS, avidin–biotin complex solution was pipetted onto object 
slides and incubated for 30 min. After washing off the avidin–
biotin complex solution, the 3-amino-9-ethylcarbazole (AEC) 
solution was added and slides were carefully observed for staining 
reaction. Reaction was then stopped through washing with aqua 
bidest. Nuclei were subsequently stained with Haemalaun solu-
tion. Tumor slides were finally embedded using mounting solu-
tion. Five 10× magnification images of every tumor and stained 
antigen, respectively, were taken (microscope Olympus BX50, 
Olympus; software Cell Imaging, Olympus) and were indepen-
dently assessed by two blinded investigators (D.T., J.W.). Each 
investigator ranked a value for the expression intensity from 0 (no 
expression) to 3 (very strong expression) and a value describing 
the extent of tumor staining (1, 0–24%; 2, 25–49%; 3, 50–74%; 
4, 75–100%). These values were multiplied. The final score of 
each tumor was then calculated as the mean of these two inde-
pendent evaluations. Consequently, lowest score was 0, highest 
score was 12. Tissues slides of healthy liver and intestine were 
used as positive controls and were provided by the tissue bank of 
the National Center of Tumor Diseases (NCT) at the institute of 
pathology at the University of Heidelberg.
Statistical analysis
Differences in tumor volumes during chemotherapy with 
5-FU vs. control were evaluated using non-parametric Mann–
Whitney test comparing tumor volumes at respective time 
points. Effects of paclitaxel or cisplatin vs. control were evaluated 
by non-parametric ANOVA with Kruskal–Wallis post-hoc test 
also comparing tumor volumes at respective time points.
Expression levels of drug transporters and Ki-67 were evalu-
ated at the end of chemotherapy. Differential expression levels 
(mRNA, protein, Ki-67 staining) and differences in body weights 
were respectively evaluated by non-parametric Mann–Whitney 
test (5-FU vs control) or non-parametric ANOVA with Kruskal–
Wallis post-hoc test (paclitaxel vs cisplatin vs control). P ≤ 0.05 
was considered significant.
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